INNOVATIONS TO IMPROVE TUBERCULOSIS THERAPY
TB therapy is wholly reliant on new drug discovery that is itself, purely serendipitous; while there has not been a new TB antibiotic introduced into clinical practice for over 50 years.
The most pressing need is to find a companion drug for pyrazinamide, or a replacement that is effective against acid arrested TB bacilli, that cause the main bottleneck in TB therapy.
Currently, the whole of TB chemotherapy is dependant on just two antibiotics, Isoniazid and Rifampacin, and without their replacement to combat MDR-TB, which is by no means guaranteed, the concern is that we will drift back to the pre-antibiotic era.
New concept adjunctive treatments can rescue antibiotics that enter chemical graveyards through bacterial dormancy or resistance, and can also increase their efficacy as well, by design, that can lead to shorter therapy duration. One such example is shown under, 'precision hyperthermia'.
INTERUPTING HOST TO HOST TRANSMISSION OF MTB
An unmet need exists to prevent Mycobacterium tuberculosis from infecting the human host irrespective of any therapeutic challenges faced in achieving this objective. Previous attempts have been made at pre-exposure prophylaxis in TB uninfected hosts that have resulted in failure.
An increased risk of Infection with X/MDR-TB strains has placed a new emphasis in avoiding a TB infection, where active disease downstream may now become a death sentence.There is a novel route available to interrupt the transmission of MTB, which I am currently exploring with a view to progressing to a proof of concept study.
copyright © Gino Francesco 2016